Anemia and Iron Deficiency in Heart Failure: Current Concepts and Emerging Therapies

Circulation

Volumn 138, Issue 1, 2018, Pages 80-98

  Anand, Inder S ^a,b,c   Gupta, Pankaj ^a,c  

^a VA MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Anemia; Erythropoietin; Heart failure; Iron; Renal insufficiency, chronic

Indexed keywords

ANTIANEMIC AGENT; FERRIC CARBOXYMALTOSE; FERRIC GLUCONATE; FERRITIN; FERUMOXYTOL; HEPCIDIN; IRON; IRON DEXTRAN; IRON ISOMALTOSIDE; IRON POLYSACCHARIDE; IRON SACCHARATE; PLACEBO; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ANAPHYLAXIS; ANEMIA; ARTHRALGIA; ARTICLE; BACKACHE; BACTEREMIA; BLOOD TRANSFUSION; BONE MARROW; CARDIOMYOPATHY; CEREBROVASCULAR ACCIDENT; CLINICAL OUTCOME; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ERYTHROCYTE CONCENTRATE; EXERCISE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART FAILURE; HEART INFARCTION; HOT FLUSH; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; HYPOTENSION; INJECTION SITE DISCOLORATION; INJECTION SITE EXTRAVASATION; INJECTION SITE IRRITATION; INJECTION SITE LEAKAGE; INJECTION SITE REACTION; IRON DEFICIENCY; IRON METABOLISM; IRON OVERLOAD; LEG CRAMP; LEG PAIN; LIMB PAIN; LONG TERM CARE; MUSCLE CRAMP; NAUSEA; OXIDATIVE STRESS; PATHOGENESIS; PATIENT CARE; PERIPHERAL EDEMA; PREVALENCE; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TACHYCARDIA; THORAX PAIN; THROMBOEMBOLISM; VOMITING; ANIMAL; BLOOD; CLINICAL DECISION MAKING; COMORBIDITY; CONVALESCENCE; DRUG EFFECT; EXERCISE TOLERANCE; IRON DEFICIENCY ANEMIA; PATHOPHYSIOLOGY; RISK FACTOR; TREATMENT OUTCOME;

ANEMIA, IRON-DEFICIENCY; ANIMALS; CLINICAL DECISION-MAKING; COMORBIDITY; EXERCISE TOLERANCE; HEART FAILURE; HEMATINICS; HUMANS; PREVALENCE; RECOVERY OF FUNCTION; RISK FACTORS; TREATMENT OUTCOME;

EID: 85054010093     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.118.030099     Document Type: Article

References (108)

1. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137- e161. doi: 10.1161/CIR.0000000000000509.
2. Writing Group Members, Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Despres JP, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jimenez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Woo D, Yeh RW, Turner MB, American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2016;133:e38-e360. doi: 10.1161/CIR.0000000000000350.
3. Anand IS. Anemia and chronic heart failure implications and treatment options. J Am Coll Cardiol. 2008;52:501-511. doi: 10.1016/j.jacc. 2008.04.044.
4. Kotecha D, Ngo K, Walters JA, Manzano L, Palazzuoli A, Flather MD. Erythropoietin as a treatment of anemia in heart failure: systematic review of randomized trials. Am Heart J. 2011;161:822-831.e2. doi: 10.1016/j.ahj.2011.02.013.
5. Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, Maggioni AP, McMurray JJ, O'Connor C, Pfeffer MA, Solomon SD, Sun Y, Tendera M, van Veldhuisen DJ; RED-HF Committees; RED-HF Investigators. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med. 2013;368:1210-1219. doi: 10.1056/NEJMoa1214865.
6. Kidney Disease Improving Global Outcomes) (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2:279-335.
7. Tang YD, Katz SD. The prevalence of anemia in chronic heart failure and its impact on the clinical outcomes. Heart Fail Rev. 2008;13:387-392. doi: 10.1007/s10741-008-9089-7.
8. O'Meara E, Clayton T, McEntegart MB, McMurray JJ, Lang CC, Roger SD, Young JB, Solomon SD, Granger CB, Ostergren J, Olofsson B, Michelson EL, Pocock S, Yusuf S, Swedberg K, Pfeffer MA; CHARM Committees and Investigators. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation. 2006;113:986-994. doi: 10.1161/CIRCULATIONAHA.105.582577.
9. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation. 2003;107:223-225.
10. Goodnough LT, Schrier SL. Evaluation and management of anemia in the elderly. Am J Hematol. 2014;89:88-96. doi: 10.1002/ajh.23598.
11. Anand IS, Kuskowski MA, Rector TS, Florea VG, Glazer RD, Hester A, Chiang YT, Aknay N, Maggioni AP, Opasich C, Latini R, Cohn JN. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-He FT. Circulation. 2005;112:1121-1127. doi: 10.1161/CIRCULATIONAHA.104.512988.
12. Opasich C, Cazzola M, Scelsi L, De Feo S, Bosimini E, Lagioia R, Febo O, Ferrari R, Fucili A, Moratti R, Tramarin R, Tavazzi L. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J. 2005;26:2232- 2237. doi: 10.1093/eurheartj/ehi388.
13. Anand IS, Rector T, Deswal A, Iverson E, Anderson S, Mann D, Cohn JN, Demets D. Relationship between proinflammatory cytokines and anemia in heart failure. Eur Heart J. 2006;27(suppl 1):485.
14. Montero D, Lundby C, Ruschitzka F, Flammer AJ. True anemia-red blood cell volume deficit-in heart failure: a systematic review. Circ Heart Fail. 2017;10:e003610. doi: 10.1161/CIRCHEARTFAILURE.116.003610.
15. McMahon LP, Mason K, Skinner SL, Burge CM, Grigg LE, Becker GJ. Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant. 2000;15:1425-1430.
16. Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L. Iron deficiency anaemia. Lancet. 2016;387:907-916. doi: 10.1016/S0140-6736(15)60865-0.
17. Anand IS, Ferrari R, Kalra GS, Wahi PL, Poole-Wilson PA, Harris PC. Pathogenesis of edema in constrictive pericarditis: studies of body water and sodium, renal function, hemodynamics, and plasma hormones before and after pericardiectomy. Circulation. 1991;83:1880-1887.
18. Anand IS, Ferrari R, Kalra GS, Wahi PL, Poole-Wilson PA, Harris PC. Edema of cardiac origin: studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation. 1989;80:299-305.
19. van der Meer P, Voors AA, Lipsic E, Smilde TD, van Gilst WH, van Veldhuisen DJ. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol. 2004;44:63-67. doi: 10.1016/j.jacc.2004.03.052.
20. Westenbrink BD, Visser FW, Voors AA, Smilde TD, Lipsic E, Navis G, Hillege HL, van Gilst WH, van Veldhuisen DJ. Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. Eur Heart J. 2007;28:166-171. doi: 10.1093/eurheartj/ehl419.
21. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation. 2001;103:2055-2059.
22. Fyhrquist F, Karppinen K, Honkanen T, Saijonmaa O, Rosenlof K. High serum erythropoietin levels are normalized during treatment of congestive heart failure with enalapril. J Intern Med. 1989;226:257-260.
23. van der Meer P, Lipsic E, Westenbrink BD, van de Wal RM, Schoemaker RG, Vellenga E, van Veldhuisen DJ, Voors AA, van Gilst WH. Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure. Circulation. 2005;112:1743- 1747. doi: 10.1161/CIRCULATIONAHA.105.549121.
24. Anand IS, Veall N, Kalra GS, Ferrari R, Sutton G, Lipkin D, Harris P, Poole- Wilson PA. Treatment of heart failure with diuretics: body compartments, renal function and plasma hormones. Eur Heart J. 1989;10:445-450.
25. Weiss G. Iron metabolism in the anemia of chronic disease. Biochim Biophys Acta. 2009;1790:682-693. doi: 10.1016/j.bbagen.2008.08.006.
26. Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, McConkey M, Gupta N, Gabriel S, Ardissino D, Baber U, Mehran R, Fuster V, Danesh J, Frossard P, Saleheen D, Melander O, Sukhova GK, Neuberg D, Libby P, Kathiresan S, Ebert BL. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377:111-121. doi: 10.1056/NEJMoa1701719.
27. Sano S, Oshima K, Wang Y, MacLauchlan S, Katanasaka Y, Sano M, Zuriaga MA, Yoshiyama M, Goukassian D, Cooper MA, Fuster JJ, Walsh K. Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1β/NLRP3 inflammasome. J Am Coll Cardiol. 2018;71:875-886. doi: 10.1016/j.jacc.2017.12.037.
28. Anand IS, Chandrashekhar Y, Ferrari R, Poole-Wilson PA, Harris PC. Pathogenesis of oedema in chronic severe anaemia: studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones. Br Heart J. 1993;70:357-362.
29. Anand IS, Chandrashekhar Y, Wander GS, Chawla LS. Endotheliumderived relaxing factor is important in mediating the high output state in chronic severe anemia. J Am Coll Cardiol. 1995;25:1402-1407. doi: 10.1016/0735-1097(95)00007-Q.
30. Ni Z, Morcos S, Vaziri ND. Up-regulation of renal and vascular nitric oxide synthase in iron-deficiency anemia. Kidney Int. 1997;52:195-201.
31. Go AS, Yang J, Ackerson LM, Lepper K, Robbins S, Massie BM, Shlipak MG. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. Circulation. 2006;113:2713-2723. doi: 10.1161/CIRCULATIONAHA.105.577577.
32. Komajda M, Anker SD, Charlesworth A, Okonko D, Metra M, Di Lenarda A, Remme W, Moullet C, Swedberg K, Cleland JG, Poole-Wilson PA. The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. Eur Heart J. 2006;27:1440-1446. doi: 10.1093/eurheartj/ehl012.
33. Sharma R, Francis DP, Pitt B, Poole-Wilson PA, Coats AJ, Anker SD. Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial. Eur Heart J. 2004;25:1021-1028. doi: 10.1016/j.ehj.2004.04.023.
34. Gagnon DR, Zhang TJ, Brand FN, Kannel WB. Hematocrit and the risk of cardiovascular disease: the Framingham study: a 34-year follow-up. Am Heart J. 1994;127:674-682.
35. Brown DW, Giles WH, Croft JB. Hematocrit and the risk of coronary heart disease mortality. Am Heart J. 2001;142:657-663. doi: 10.1067/mhj.2001.118467.
36. Sabatine MS, Morrow DA, Giugliano RP, Burton PB, Murphy SA, McCabe CH, Gibson CM, Braunwald E. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation. 2005;111:2042- 2049. doi: 10.1161/01.CIR.0000162477.70955.5F.
37. Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, van der Meer P. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol. 2008;52:818-827. doi: 10.1016/j.jacc.2008.04.061.
38. Tang WH, Tong W, Jain A, Francis GS, Harris CM, Young JB. Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure. J Am Coll Cardiol. 2008;51:569-576. doi: 10.1016/j.jacc.2007.07.094.
39. Herzog CA, Muster HA, Li S, Collins AJ. Impact of congestive heart failure, chronic kidney disease, and anemia on survival in the Medicare population. J Card Fail. 2004;10:467-472.
40. Datta BN, Silver MD. Cardiomegaly in chronic anaemia in rats; gross and histologic features. Indian J Med Res. 1976;64:447-458.
41. Anand I, McMurray JJ, Whitmore J, Warren M, Pham A, McCamish MA, Burton PB. Anemia and its relationship to clinical outcome in heart failure. Circulation. 2004;110:149-154. doi: 10.1161/01.CIR.0000134279.79571.73.
42. Kao DP, Kreso E, Fonarow GC, Krantz MJ. Characteristics and outcomes among heart failure patients with anemia and renal insufficiency with and without blood transfusions (public discharge data from California 2000-2006). Am J Cardiol. 2011;107:69-73. doi: 10.1016/j.amjcard.2010.08.046.
43. Mazer CD, Whitlock RP, Fergusson DA, Hall J, Belley-Cote E, Connolly K, Khanykin B, Gregory AJ, de Medicis E, McGuinness S, Royse A, Carrier FM, Young PJ, Villar JC, Grocott HP, Seeberger MD, Fremes S, Lellouche F, Syed S, Byrne K, Bagshaw SM, Hwang NC, Mehta C, Painter TW, Royse C, Verma S, Hare GMT, Cohen A, Thorpe KE, Juni P, Shehata N; TRICS Investigators and Perioperative Anesthesia Clinical Trials Group. Restrictive or liberal red-cell transfusion for cardiac surgery. N Engl J Med. 2017;377:2133-2144. doi: 10.1056/NEJMoa1711818.
44. Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenberg B, Krum H, Massie BM, Wasserman SM, Trotman ML, Sun Y, Knusel B, Armstrong P; Study of Anemia in Heart Failure Trial (STAMINA-HeFT) Group. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation. 2008;117:526-535. doi: 10.1161/CIRCULATIONAHA.107.698514.
45. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet. 2007;369:381-388. doi: 10.1016/S0140-6736(07)60194-9.
46. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584-590. doi: 10.1056/NEJM199808273390903.
47. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A; CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071-2084. doi: 10.1056/NEJMoa062276.
48. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085-2098. doi: 10.1056/NEJMoa065485.
49. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R; TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019-2032. doi: 10.1056/NEJMoa0907845.
50. Desai A, Lewis E, Solomon S, McMurray JJ, Pfeffer M. Impact of erythropoiesis- stimulating agents on morbidity and mortality in patients with heart failure: an updated, post-TREAT meta-analysis. Eur J Heart Fail. 2010;12:936-942. doi: 10.1093/eurjhf/hfq094.
51. US Food and Drug Administration. https://www.accessdata.fda.gov/ scripts/cder/daf/. Accessed May 23, 2018.
52. Kliger AS, Foley RN, Goldfarb DS, Goldstein SL, Johansen K, Singh A, Szczech L. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD. Am J Kidney Dis. 2013;62:849-859. doi: 10.1053/j.ajkd.2013.06.008.
53. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, Salio M, Cerami A, Brines M. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A. 2003;100:4802-4806. doi: 10.1073/pnas.0630444100.
54. Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, de Zeeuw D, Ivanovich P, Levey AS, Parfrey P, Remuzzi G, Singh AK, Toto R, Huang F, Rossert J, McMurray JJ, Pfeffer MA; Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Investigators. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010;363:1146-1155. doi: 10.1056/NEJMoa1005109.
55. Dunn LL, Suryo Rahmanto Y, Richardson DR. Iron uptake and metabolism in the new millennium. Trends Cell Biol. 2007;17:93-100. doi: 10.1016/j.tcb.2006.12.003.
56. Melenovsky V, Petrak J, Mracek T, Benes J, Borlaug BA, Nuskova H, Pluhacek T, Spatenka J, Kovalcikova J, Drahota Z, Kautzner J, Pirk J, Houstek J. Myocardial iron content and mitochondrial function in human heart failure: a direct tissue analysis. Eur J Heart Fail. 2017;19:522-530. doi: 10.1002/ejhf.640.
57. Jankowska EA, Ponikowski P. Molecular changes in myocardium in the course of anemia or iron deficiency. Heart Fail Clin. 2010;6:295-304. doi: 10.1016/j.hfc.2010.03.003.
58. Yeo TJ, Yeo PS, Ching-Chiew Wong R, Ong HY, Leong KT, Jaufeerally F, Sim D, Santhanakrishnan R, Lim SL, M Y Chan M, Chai P, Low AF, Ling LH, Ng TP, Richards AM, Lam CS. Iron deficiency in a multi-ethnic Asian population with and without heart failure: prevalence, clinical correlates, functional significance and prognosis. Eur J Heart Fail. 2014;16:1125-1132. doi: 10.1002/ejhf.161.
59. Martens P, Nijst P, Verbrugge FH, Smeets K, Dupont M, Mullens W. Impact of iron deficiency on exercise capacity and outcome in heart failure with reduced, mid-range and preserved ejection fraction. Acta Cardiol. 2017;73:1-9. doi: 10.1080/00015385.2017.1351239.
60. Cappellini MD, Comin-Colet J, de Francisco A, Dignass A, Doehner W, Lam CS, Macdougall IC, Rogler G, Camaschella C, Kadir R, Kassebaum NJ, Spahn DR, Taher AT, Musallam KM; IRON CORE Group. Iron deficiency across chronic inflammatory conditions: international expert opinion on definition, diagnosis, and management. Am J Hematol. 2017;92:1068- 1078. doi: 10.1002/ajh.24820.
61. Klip IT, Comin-Colet J, Voors AA, Ponikowski P, Enjuanes C, Banasiak W, Lok DJ, Rosentryt P, Torrens A, Polonski L, van Veldhuisen DJ, van der Meer P, Jankowska EA. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. 2013;165:575-582.e3. doi: 10.1016/j.ahj.2013.01.017.
62. Anand I. Iron deficiency in heart failure. Cardiology. 2014;128:317-319. doi: 10.1159/000361040.
63. Jankowska EA, Malyszko J, Ardehali H, Koc-Zorawska E, Banasiak W, von Haehling S, Macdougall IC, Weiss G, McMurray JJ, Anker SD, Gheorghiade M, Ponikowski P. Iron status in patients with chronic heart failure. Eur Heart J. 2013;34:827-834. doi: 10.1093/eurheartj/ehs377.
64. Alexandrakis MG, Tsirakis G. Anemia in heart failure patients. ISRN Hematol. 2012;2012:246915. doi: 10.5402/2012/246915.
65. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352:1011-1023. doi: 10.1056/NEJMra041809.
66. von Haehling S, Jankowska EA, van Veldhuisen DJ, Ponikowski P, Anker SD. Iron deficiency and cardiovascular disease. Nat Rev Cardiol. 2015;12:659-669. doi: 10.1038/nrcardio.2015.109.
67. Skikne BS, Punnonen K, Caldron PH, Bennett MT, Rehu M, Gasior GH, Chamberlin JS, Sullivan LA, Bray KR, Southwick PC. Improved differential diagnosis of anemia of chronic disease and iron deficiency anemia: a prospective multicenter evaluation of soluble transferrin receptor and the sTfR/log ferritin index. Am J Hematol. 2011;86:923-927. doi: 10.1002/ajh.22108.
68. Girelli D, Nemeth E, Swinkels DW. Hepcidin in the diagnosis of iron disorders. Blood. 2016;127:2809-2813. doi: 10.1182/blood-2015-12-639112.
69. Mwangi MN, Maskey S, Andang o PE, Shinali NK, Roth JM, Trijsburg L, Mwangi AM, Zuilhof H, van Lagen B, Savelkoul HF, Demir AY, Verhoef H. Diagnostic utility of zinc protoporphyrin to detect iron deficiency in Kenyan pregnant women. BMC Med. 2014;12:229. doi: 10.1186/s12916-014-0229-8.
70. Grote Beverborg N, Klip IT, Meijers WC, Voors AA, Vegter EL, van der Wal HH, Swinkels DW, van Pelt J, Mulder AB, Bulstra SK, Vellenga E, Mariani MA, de Boer RA, van Veldhuisen DJ, van der Meer P. Definition of iron deficiency based on the gold standard of bone marrow iron staining in heart failure patients. Circ Heart Fail. 2018;11:e004519. doi: 10.1161/CIRCHEARTFAILURE.117.004519.
71. Jankowska EA, Wojtas K, Kasztura M, Mazur G, Butrym A, Kalicinska E, Rybinska I, Skiba J, von Haehling S, Doehner W, Anker SD, Banasiak W, Cleland JG, Ponikowski P. Bone marrow iron depletion is common in patients with coronary artery disease. Int J Cardiol. 2015;182:517-522. doi: 10.1016/j.ijcard.2014.10.006.
72. Infusino I, Braga F, Dolci A, Panteghini M. Soluble transferrin receptor (sTfR) and sTfR/log ferritin index for the diagnosis of iron-deficiency anemia: a meta-analysis. Am J Clin Pathol. 2012;138:642-649. doi: 10.1309/AJCP16NTXZLZFAIB.
73. Wish JB. Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol. 2006;1(suppl 1):S4-S8. doi: 10.2215/CJN.01490506.
74. van Santen S, van Dongen-Lases EC, de Vegt F, Laarakkers CM, van Riel PL, van Ede AE, Swinkels DW. Hepcidin and hemoglobin content parameters in the diagnosis of iron deficiency in rheumatoid arthritis patients with anemia. Arthritis Rheum. 2011;63:3672-3680. doi: 10.1002/art.30623.
75. Nanas JN, Matsouka C, Karageorgopoulos D, Leonti A, Tsolakis E, Drakos SG, Tsagalou EP, Maroulidis GD, Alexopoulos GP, Kanakakis JE, Anastasiou- Nana MI. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol. 2006;48:2485-2489. doi: 10.1016/j.jacc.2006.08.034.
76. Dale JC, Burritt MF, Zinsmeister AR. Diurnal variation of serum iron, ironbinding capacity, transferrin saturation, and ferritin levels. Am J Clin Pathol. 2002;117:802-808. doi: 10.1309/2YT4-CMP3-KYW7-9RK1.
77. Brownlie T 4th, Utermohlen V, Hinton PS, Haas JD. Tissue iron deficiency without anemia impairs adaptation in endurance capacity after aerobic training in previously untrained women. Am J Clin Nutr. 2004;79:437-443. doi: 10.1093/ajcn/79.3.437.
78. Dong F, Zhang X, Culver B, Chew HG Jr, Kelley RO, Ren J. Dietary iron deficiency induces ventricular dilation, mitochondrial ultrastructural aberrations and cytochrome c release: involvement of nitric oxide synthase and protein tyrosine nitration. Clin Sci (Lond). 2005;109:277-286. doi: 10.1042/CS20040278.
79. Maeder MT, Khammy O, dos Remedios C, Kaye DM. Myocardial and systemic iron depletion in heart failure implications for anemia accompanying heart failure. J Am Coll Cardiol. 2011;58:474-480. doi: 10.1016/j.jacc.2011.01.059.
80. Xu W, Barrientos T, Mao L, Rockman HA, Sauve AA, Andrews NC. Lethal cardiomyopathy in mice lacking transferrin receptor in the heart. Cell Rep. 2015;13:533-545. doi: 10.1016/j.celrep.2015.09.023.
81. Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, Borodulin-Nadzieja L, von Haehling S, Doehner W, Banasiak W, Polonski L, Filippatos G, Anker SD, Ponikowski P. Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure. J Card Fail. 2011;17:899-906. doi: 10.1016/j.cardfail.2011.08.003.
82. Enjuanes C, Klip IT, Bruguera J, Cladellas M, Ponikowski P, Banasiak W, van Veldhuisen DJ, van der Meer P, Jankowska EA, Comin-Colet J. Iron deficiency and health-related quality of life in chronic heart failure: results from a multicenter European study. Int J Cardiol. 2014;174:268-275. doi: 10.1016/j.ijcard.2014.03.169.
83. Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, Borodulin-Nadzieja L, Banasiak W, Polonski L, Filippatos G, Mc- Murray JJ, Anker SD, Ponikowski P. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J. 2010;31:1872-1880. doi: 10.1093/eurheartj/ehq158.
84. Avni T, Leibovici L, Gafter-Gvili A. Iron supplementation for the treatment of chronic heart failure and iron deficiency: systematic review and meta-analysis. Eur J Heart Fail. 2012;14:423-429. doi: 10.1093/ eurjhf/hfs017.
85. Jankowska EA, Tkaczyszyn M, Suchocki T, Drozd M, von Haehling S, Doehner W, Banasiak W, Filippatos G, Anker SD, Ponikowski P. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. Eur J Heart Fail. 2016;18:786-795. doi: 10.1002/ejhf.473.
86. Kapoor M, Schleinitz MD, Gemignani A, Wu WC. Outcomes of patients with chronic heart failure and iron deficiency treated with intravenous iron: a meta-analysis. Cardiovasc Hematol Disord Drug Targets. 2013;13:35-44.
87. Qian C, Wei B, Ding J, Wu H, Wang Y. The efficacy and safety of iron supplementation in patients with heart failure and iron deficiency: a systematic review and meta-analysis. Can J Cardiol. 2016;32:151-159. doi: 10.1016/j.cjca.2015.06.009.
88. Anker SD, Kirwan BA, van Veldhuisen DJ, Filippatos G, Comin-Colet J, Ruschitzka F, Luscher TF, Arutyunov GP, Motro M, Mori C, Roubert B, Pocock SJ, Ponikowski P. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. Eur J Heart Fail. 2018;20:125-133. doi: 10.1002/ejhf.823.
89. Bolger AP, Bartlett FR, Penston HS, O'Leary J, Pollock N, Kaprielian R, Chapman CM. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol. 2006;48:1225-1227. doi: 10.1016/j.jacc.2006.07.015.
90. Usmanov RI, Zueva EB, Silverberg DS, Shaked M. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. J Nephrol. 2008;21:236-242.
91. Toblli JE, Lombrana A, Duarte P, Di Gennaro F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol. 2007;50:1657-1665. doi: 10.1016/j.jacc.2007.07.029.
92. Okonko DO, Grzeslo A, Witkowski T, Mandal AK, Slater RM, Roughton M, Foldes G, Thum T, Majda J, Banasiak W, Missouris CG, Poole-Wilson PA, Anker SD, Ponikowski P. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol. 2008;51:103-112. doi: 10.1016/j.jacc.2007.09.036.
93. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P; FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361:2436-2448. doi: 10.1056/NEJMoa0908355.
94. Ponikowski P, Filippatos G, Colet JC, Willenheimer R, Dickstein K, Luscher T, Gaudesius G, von Eisenhart Rothe B, Mori C, Greenlaw N, Ford I, Macdougall I, Anker SD; FAIR-HF Trial Investigators. The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study. Eur J Heart Fail. 2015;17:329-339. doi: 10.1002/ejhf.229.
95. Koch TA, Myers J, Goodnough LT. Intravenous iron therapy in patients with iron deficiency anemia: dosing considerations. Anemia. 2015;2015:763576. doi: 10.1155/2015/763576.
96. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD; CONFIRM-HF Investigators. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015;36:657-668. doi: 10.1093/ eurheartj/ehu385.
97. van Veldhuisen DJ, Ponikowski P, van der Meer P, Metra M, Bohm M, Doletsky A, Voors AA, Macdougall IC, Anker SD, Roubert B, Zakin L, Cohen-Solal A; EFFECT-HF Investigators. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation. 2017;136:1374-1383. doi: 10.1161/CIRCULATIONAHA. 117.027497.
98. Ganz T. Hepcidin and iron regulation, 10 years later. Blood. 2011;117:4425-4433. doi: 10.1182/blood-2011-01-258467.
99. Beck-da-Silva L, Piardi D, Soder S, Rohde LE, Pereira-Barretto AC, de Albuquerque D, Bocchi E, Vilas-Boas F, Moura LZ, Montera MW, Rassi S, Clausell N. IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia. Int J Cardiol. 2013;168:3439-3442. doi: 10.1016/j.ijcard.2013.04.181.
100. Lewis GD, Malhotra R, Hernandez AF, McNulty SE, Smith A, Felker GM, Tang WHW, LaRue SJ, Redfield MM, Semigran MJ, Givertz MM, Van Buren P, Whellan D, Anstrom KJ, Shah MR, Desvigne-Nickens P, Butler J, Braunwald E; NHLBI Heart Failure Clinical Research Network. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial. JAMA. 2017;317:1958-1966. doi: 10.1001/jama. 2017.5427.
101. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P and Group ESCSD. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129-2200. doi: 10.1093/eurheartj/ehw128.
102. Ganz T, Nemeth E. Iron imports, IV: hepcidin and regulation of body iron metabolism. Am J Physiol Gastrointest Liver Physiol. 2006;290:G199- G203. doi: 10.1152/ajpgi.00412.2005.
103. Hamanaka RB, Chandel NS. Mitochondrial reactive oxygen species regulate cellular signaling and dictate biological outcomes. Trends Biochem Sci. 2010;35:505-513. doi: 10.1016/j.tibs.2010.04.002.
104. Murphy CJ, Oudit GY. Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment. J Card Fail. 2010;16:888-900. doi: 10.1016/j.cardfail.2010.05.009.
105. Sullivan JL. Long-term risks of increased use of intravenous iron. Lancet. 2007;370:481-482. doi: 10.1016/S0140-6736(07)61225-2.
106. Gammella E, Recalcati S, Rybinska I, Buratti P, Cairo G. Iron-induced damage in cardiomyopathy: oxidative-dependent and independent mechanisms. Oxid Med Cell Longev. 2015;2015:230182. doi: 10.1155/2015/230182.
107. Grote Beverborg N, van Veldhuisen DJ, van der Meer P. Anemia in heart failure: still relevant? JACC Heart Fail. 2018;6:201-208. doi: 10.1016/j.jchf.2017.08.023.
108. Mleczko-Sanecka K, da Silva AR, Call D, Neves J, Schmeer N, Damm G, Seehofer D, Muckenthaler MU. Imatinib and spironolactone suppress hepcidin expression. Haematologica. 2017;102:1173-1184. doi: 10.3324/haematol.2016.162917.